Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting, 9522-9523 [2021-03047]
Download as PDF
<![CDATA[
9522
Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this invention. Interested
parties should have the ability to
manufacture viruses under cGMP,
suitable for Phase 1–2 testing by NIAID.
Capabilities for further clinical
development, and experience with
Phase 3 testing, licensure, and rollout
are preferred. For collaboration
opportunities, please contact Chris
Kornak at chris.kornak@nih.gov.
Dated: January 29, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2021–03044 Filed 2–12–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Notice is hereby given of a meeting of
the HEAL (Helping to End Addiction
Long-term) Multi-Disciplinary Working
Group
The meeting will be open to the
public as indicated below via NIH
Videocast. Individuals who need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
Contact Person listed below in advance
of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The program documents
and the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the program
documents, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: HEAL MultiDisciplinary Working Group Meeting.
Date: March 2–3, 2021.
Open: March 02, 2021, 11:00 a.m. to 12:20
p.m.
Closed: March 02, 2021, 12:20 p.m. to 4:30
p.m.
Open: March 03, 2021, 10:30 a.m. to 11:05
a.m.
Closed: March 03, 2021, 11:05 a.m. to 2:45
p.m.
VerDate Sep<11>2014
17:04 Feb 12, 2021
Jkt 253001
Agenda: Provide an update on Helping to
End Addiction Long-Term (HEAL) Initiative
projects and obtain expertise from MDWG
relevant to the NIH HEAL Initiative and to
specific HEAL projects.
Videocast: The open portion of the meeting
will be live webcast at: https://
videocast.nih.gov/.
Place: National Institutes of Health
Building 1, Wilson Hall, 1 Center Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Rebecca G Baker, Ph.D.,
Office of the Director, National Institutes of
Health, 1 Center Drive, Room 103A,
Bethesda, MD 20892, (301) 402–1994,
Rebecca.baker@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the Office
of the Director for the NIH HEAL Initiative
home page: https://heal.nih.gov/news where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: February 9, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–03018 Filed 2–12–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency
Coordinating Committee Meeting
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Diabetes Mellitus
Interagency Coordinating Committee
(DMICC) will hold a meeting on March
3, 2021. The topic for this meeting will
be ‘‘COVID–19 and Diabetes.’’ The
meeting is open to the public.
DATES: The meeting will be held on
March 3, 2021 from 12 noon to 4:00
p.m. EST.
ADDRESSES: The meeting will be held
via the online video conferencing—
Zoom. For details, and to register, please
contact dmicc@mail.nih.gov.
FOR FURTHER INFORMATION CONTACT: For
further information concerning this
meeting, including a draft agenda, see
the DMICC website,
www.diabetescommittee.gov, or contact
SUMMARY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Dr. B. Tibor Roberts, Executive
Secretary of the Diabetes Mellitus
Interagency Coordinating Committee,
National Institute of Diabetes and
Digestive and Kidney Diseases, 31
Center Drive, Building 31A, Room
9A19, MSC 2560, Bethesda, MD 20892–
2560, telephone: 301–496–6623; FAX:
301–480–6741; email: dmicc@
mail.nih.gov.
In
accordance with 42 U.S. Code 285c–3,
the DMICC, chaired by the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising
members of the Department of Health
and Human Services and other federal
agencies that support diabetes-related
activities, facilitates cooperation,
communication, and collaboration on
diabetes among government entities.
DMICC meetings, held several times a
year, provide an opportunity for
Committee members to learn about and
discuss current and future diabetes
programs in DMICC member
organizations and to identify
opportunities for collaboration. The
March 3, 2021 DMICC meeting will
focus on ‘‘COVID–19 and Diabetes.’’
Any member of the public interested
in presenting oral comments to the
Committee should notify the contact
person listed on this notice at least 5
days in advance of the meeting.
Interested individuals and
representatives or organizations should
submit a letter of intent, a brief
description of the organization
represented, and a written copy of their
oral presentation in advance of the
meeting. Only one representative of an
organization will be allowed to present;
oral comments and presentations will be
limited to a maximum of 5 minutes.
Printed and electronic copies are
requested for the record. In addition,
any interested person may file written
comments with the Committee by
forwarding their statement to the
contact person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Because of time constraints for the
meeting, oral comments will be allowed
on a first-come, first-serve basis.
Members of the public who would
like to receive email notification about
future DMICC meetings should register
for the listserv available on the DMICC
website, www.diabetescommittee.gov.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\16FEN1.SGM
16FEN1
Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices
Dated: February 4, 2021.
Bruce Tibor Roberts,
Executive Secretary, DMICC, Office of
Scientific Program and Policy Analysis,
National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of
Health.
[FR Doc. 2021–03047 Filed 2–12–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR18–877:
Alzheimer’s Disease Clinical Trials.
Date: March 10, 2021.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Sara Louise Hargrave,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 3170,
Bethesda, MD 20892, (301) 443–7193,
hargravesl@mail.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Biostatistical Methods and Research Design
Study Section.
Date: March 10–12, 2021.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Victoriya Volkova,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3140,
Bethesda, MD 20892, (301) 594–7781,
victoriya.volkova@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Biostatistical Methods and Research Design.
Date: March 12, 2021.
VerDate Sep<11>2014
17:04 Feb 12, 2021
Jkt 253001
Time: 9:30 a.m. to 11:30 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Seetha Bhagavan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5194,
MSC 7846, Bethesda, MD 20892, (301) 237–
9838, bhagavas@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cancer Diagnostics and Treatments
(CDT).
Date: March 15–16, 2021.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maria Elena CardenasCorona, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20817, (301) 867–5309, maria.cardenascorona@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR Panel:
Community Interventions to Address the
Consequences of the COVID–19 Pandemic
Among Health Disparity and Vulnerable
Populations.
Date: March 15–16, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Pia Kristina Peltola, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 435–1266,
pia.peltola@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Disease Prevention and
Management, Risk Reduction and Health
Behavior Change.
Date: March 15–16, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Michael J. McQuestion,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7808, Bethesda, MD 20892, (301) 480–
1276, mike.mcquestion@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Infectious
Diseases and Immunology Research
Enhancement Review.
Date: March 15, 2021.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
9523
Contact Person: Liangbiao Zheng, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3202,
MSC 7808, Bethesda, MD 20892, (301) 996–
5819, zhengli@csr.nih.gov.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group;
HIV/AIDS Intra- and Inter-personal
Determinants and Behavioral Interventions
Study Section.
Date: March 15–16, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Mark P. Rubert, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, (301) 806–
6596, rubertm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Electronic Nicotine Delivery Systems
(ENDS): Population, Clinical and Applied
Prevention Research.
Date: March 15, 2021.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Miriam Mintzer, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3108,
MSC 7808, Bethesda, MD 20892, (301) 523–
0646, mintzermz@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; SBIR/STTR
Applications in Drug Discovery and
Development.
Date: March 15–16, 2021.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sergei Ruvinov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4158,
MSC 7806, Bethesda, MD 20892, (301) 435–
1180, ruvinser@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Electronic Nicotine Delivery Systems
(ENDS): Population, Clinical and Applied
Prevention Research.
Date: March 15, 2021.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mark A. Vosvick, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110,
E:\FR\FM\16FEN1.SGM
16FEN1
]]>Agencies
[Federal Register Volume 86, Number 29 (Tuesday, February 16, 2021)]
[Notices]
[Pages 9522-9523]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03047]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency Coordinating Committee
Meeting
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee
(DMICC) will hold a meeting on March 3, 2021. The topic for this
meeting will be ``COVID-19 and Diabetes.'' The meeting is open to the
public.
DATES: The meeting will be held on March 3, 2021 from 12 noon to 4:00
p.m. EST.
ADDRESSES: The meeting will be held via the online video conferencing--
Zoom. For details, and to register, please contact [email protected].
FOR FURTHER INFORMATION CONTACT: For further information concerning
this meeting, including a draft agenda, see the DMICC website,
www.diabetescommittee.gov, or contact Dr. B. Tibor Roberts, Executive
Secretary of the Diabetes Mellitus Interagency Coordinating Committee,
National Institute of Diabetes and Digestive and Kidney Diseases, 31
Center Drive, Building 31A, Room 9A19, MSC 2560, Bethesda, MD 20892-
2560, telephone: 301-496-6623; FAX: 301-480-6741; email:
[email protected].
SUPPLEMENTARY INFORMATION: In accordance with 42 U.S. Code 285c-3, the
DMICC, chaired by the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising members of the Department of Health
and Human Services and other federal agencies that support diabetes-
related activities, facilitates cooperation, communication, and
collaboration on diabetes among government entities. DMICC meetings,
held several times a year, provide an opportunity for Committee members
to learn about and discuss current and future diabetes programs in
DMICC member organizations and to identify opportunities for
collaboration. The March 3, 2021 DMICC meeting will focus on ``COVID-19
and Diabetes.''
Any member of the public interested in presenting oral comments to
the Committee should notify the contact person listed on this notice at
least 5 days in advance of the meeting. Interested individuals and
representatives or organizations should submit a letter of intent, a
brief description of the organization represented, and a written copy
of their oral presentation in advance of the meeting. Only one
representative of an organization will be allowed to present; oral
comments and presentations will be limited to a maximum of 5 minutes.
Printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
Committee by forwarding their statement to the contact person listed on
this notice. The statement should include the name, address, telephone
number and when applicable, the business or professional affiliation of
the interested person. Because of time constraints for the meeting,
oral comments will be allowed on a first-come, first-serve basis.
Members of the public who would like to receive email notification
about future DMICC meetings should register for the listserv available
on the DMICC website, www.diabetescommittee.gov.
[[Page 9523]]
Dated: February 4, 2021.
Bruce Tibor Roberts,
Executive Secretary, DMICC, Office of Scientific Program and Policy
Analysis, National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health.
[FR Doc. 2021-03047 Filed 2-12-21; 8:45 am]
BILLING CODE 4140-01-P
